COVID-19 Clinical Trials

The overall purpose of the biobank is to collect and store biological specimens, such as blood, urine, respiratory specimens, other bodily fluids, and tissue where available, as well as health information of people who may or may not have been exposed to the SARS-CoV-2 virus as well as those who have developed COVID-19 disease.. Storing these samples and this information allows researchers to use them for research studies, including but not limited to COVID-19.

Penn Medicine is seeking plasma donation from eligible healthy volunteers for a research study. Interested volunteers must have recovered from a COVID-19 positive diagnosis (made by collection of a swab of the nose or throat).

The PATCH trial tests hydroxychloroquine as a treatment in patients with COVID-19 and a preventative medication in health care workers

A double-blind placebo controlled trial of high dose hydroxychloroquine (HCQ) as a treatment for COVID-19 positive patients who are quarantined at home.

Determine how safe and tolerable a new coronavirus (COVID-19) vaccine is when given to healthy volunteers, examine the effect of the vaccine and the device on immune cells against the virus that causes COVID-19 disease, and determine possible risks and benefits of the vaccine.

The purpose of this study is to understand how the body learns to fight infections, through influenza vaccination or after SARS-CoV2 infection that causes COVID-19.

A randomized study testing different doses of hydroxychloroquine (HQC) in hospitalized COVID-19 patients.

A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID. This study is for patients in the hospital being treated for COVID-19

This study is for patients in the hospital being treated for COVID-19

The purpose of this study is to see if Remdesivir (RDV) can improve your health from being sick with COVID-19 infection. The other purpose of this study is to test if RDV is safe and tolerated by people with moderate COVID-19.

The Randomized Elimination or ProLongation of Angiotensin Converting Enzyme inhibitors and angiotensin receptor blockers in Coronavirus Disease 2019. The purpose of the study is to compare the effect of stopping versus continuing ACEI or ARBs in patients who have COVID-19.